(UroToday.com) The results from STAMPEDE Arm G comparing standard of care (SOC) to SOC plus the addition of abiraterone acetate in men with hormone-sensitive locally advanced or metastatic prostate cancer were initially presented and published in 2017. This data showed an overall survival benefit for the SOC + abiraterone arm. Subsequent analyses of this cohort have focused on the metastatic (M1) population alone and examined clinical outcomes in patients when stratified by risk criteria as defined by the LATITUDE and CHAARTED studies. Within M1 patients, the benefit of the addition to abiraterone acetate was confirmed in both low and high-risk patients by LATITUDE criteria (at least 2 of 3+ bone mets, visceral mets or Gleason score 8+).